<
Breakthrough Therapies in Dermatology Management: Advances in Atopic Dermatitis for Managed Care and Payer Professionals
Jointly provided by

This activity is supported by independent educational grants from Incyte Corporation, Pfizer Inc., Sanofi Genzyme and Regeneron Pharmaceuticals, Inc.

These live webcasts are now complete!
An on-demand CE archive is coming soon.

Until then, please visit www.impactedu.net for more free CE activities.

LEARN ABOUT
  • Recently approved and emerging Atopic Dermatitis therapies
  • The spectrum of clinical and patient-reported signs, symptoms and burden of AD
  • Recently approved and emerging agents and how they are integrated with current AD managed care treatment algorithms.
EXPERT FACULTY PRESENTERS
John Fox, MD, MHA
Chief Boundary Spanner
Foxworthy Healthcare Consulting, PLLC 		Adam Friedman, MD, FAAD
Professor and Chair of Dermatology
Associate Residency Program Director
Director of Translational Research
Director of Supportive Oncodermatology
Department of Dermatology
George Washington School of Medicine and Health Sciences
Edmund Pezalla, MD, MPH
CEO
Enlightenment Bioconsult, LLC 		Amanda Isabel Lopez, PTA, CCI
NEA Ambassador/Community Advocate
 (Track 1 only)
Ashley Ellis, PharmD, CDECS
NEA Ambassador/Community Advocate
 (Track 2 only)
TARGET AUDIENCE
  • The primary target audience for this initiative consists of medical directors, registered nurses, pharmacy directors, clinical pharmacists, specialty pharmacists, quality directors, as well as network physicians affiliated with various MCOs, health systems, and other payer organizations.
PROGRAM OVERVIEW

The evolving AD treatment landscape accentuates the need for increased disease and therapeutic knowledge amongst managed care, specialty pharmacy, and other payer professionals to provide enhanced clinical and economic outcomes to beneficiaries with AD. In addition, payer decision makers need instruction on benefit design strategies that can support an improvement in overall outcomes in patients with AD.

EDUCATIONAL OBJECTIVES

At the conclusion of this activity, participants should be able to demonstrate improved ability to:
Track 1: Breakthrough Therapies in Atopic Dermatitis Management: Clinical Evidence for Current and Emerging AD Therapies and Payer Approaches
  • Examine the pathophysiology, burden, signs and symptoms, and heterogeneity of atopic dermatitis (AD)
  • Assess the latest therapeutic developments for the treatment of AD
  • Identify the gold standard of payer benefit management strategy for AD
  • Employ timely referral and collaborative, multidisciplinary management of AD patients
    		•


    Track 2: Breakthrough Therapies in Atopic Dermatitis Management: Patient Management Strategies to Enhance Outcomes
  • Evaluate the challenges of treatment for patients with atopic dermatitis and comorbidities
  • Employ timely referral and collaborative, multidisciplinary management of patients with AD
  • Utilize treatment optimization approaches to balance costs with improved outcomes in AD disease management
    		•


    AGENDA

    Track 1: Breakthrough Therapies in Atopic Dermatitis Management: Clinical Evidence for Current and Emerging AD Therapies and Payer Approaches

    Presentation Faculty
    Pre-Activity Learning Assessment and Opening Comments/Overview Edmund Pezalla, MD, MPH
    Reducing the Burden of Atopic Dermatitis with Current and Emerging Therapies Adam Friedman, MD, FAAD
    Integration of Recent Clinical Findings into Payer Benefit Management Strategies John Fox, MD, MHA
    Case Discussion RE: Case: “Integrating Recent Clinical Findings into the Management of Atopic Dermatitis” Edmund Pezalla, MD, MPH; Adam Friedman, MD, FAAD; John Fox, MD, MHA; Amanda Isabel Lopez, PTA, CCI
    Audience Question and Answer Session, Key Takeaways, and Closing Comments All


    Track 2: Breakthrough Therapies in Atopic Dermatitis Management: Patient Management Strategies to Enhance Outcomes

    Presentation Faculty
    Pre-Activity Learning Assessment and Opening Comments/Overview Edmund Pezalla, MD, MPH
    Addressing Barriers that Limit Optimal Management of Atopic Dermatitis John Fox, MD, MHA
    Patient Management Strategies to Enhance AD Treatment Outcomes Adam Friedman, MD, FAAD
    Case Study: Overcoming Barriers to Optimal Management of Atopic Dermatitis Edmund Pezalla, MD, MPH
    Case Discussion Edmund Pezalla, MD, MPH; Adam Friedman, MD, FAAD; John Fox, MD, MHA; Ashley Ellis, PharmD, CDECS
    Audience Question and Answer Session, Key Takeaways, and Closing Comments All


    ACCREDITATION INFORMATION
    Joint Accreditation Statement
    In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine, the National Eczema Association and Impact Education, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    Physician Continuing Medical Education (per track)
    The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Track 1: Breakthrough Therapies in Atopic Dermatitis Management: Clinical Evidence for Current and Emerging AD Therapies and Payer Approaches - 1.5 AMA PRA Category 1 Credits™
    Track 2: Breakthrough Therapies in Atopic Dermatitis Management: Patient Management Strategies to Enhance Outcomes - 1.5 AMA PRA Category 1 Credits™

    Continuing Pharmacy Education (per track)
    Postgraduate Institute for Medicine designates this continuing education activity for 1.5 contact hours (0.15 CEUs) of the Accreditation Council for Pharmacy Education.

    Track 1: Breakthrough Therapies in Atopic Dermatitis Management: Clinical Evidence for Current and Emerging AD Therapies and Payer Approaches - 1.5 contact hours (0.15 CEUs)
    Universal Activity Number: JA4008162-9999-21-441-L01-P
    Type of Activity: Knowledge

    Track 2: Breakthrough Therapies in Atopic Dermatitis Management: Patient Management Strategies to Enhance Outcomes - 1.5 contact hours (0.15 CEUs)
    Universal Activity Number: JA4008162-9999-22-500-L01-P
    Type of Activity: Knowledge

    Continuing Nursing Education (per track)
    The maximum number of hours awarded for this Continuing Nursing Education activity is 1.5 contact hours.

    Track 1:Breakthrough Therapies in Atopic Dermatitis Management: Clinical Evidence for Current and Emerging AD Therapies and Payer Approaches - 1.5 contact hours
    Track 2: Breakthrough Therapies in Atopic Dermatitis Management: Patient Management Strategies to Enhance Outcomes - 1.5 contact hours

    Disclosure of Conflicts of Interest
    Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

    Hardware/Software Requirements
    Compatible with Internet Explorer 6 and up, Mozilla Firefox 3 and up, Safari 4.0, and Google Chrome 10 and up.

    Fee Information
    There is no fee for this educational activity.

    If you have any questions, please call (215) 619-8812 or email info@impactedu.net.